Skip to main content
. Author manuscript; available in PMC: 2021 Mar 15.
Published in final edited form as: Cell Rep. 2021 Feb 9;34(6):108726. doi: 10.1016/j.celrep.2021.108726

Figure 5. Small GOF p53-containing EVs promote tumor growth and CAF transformation in mouse models.

Figure 5.

(A) Tumor weights and volumes in mice inoculated with HT29 cells subcutaneously. Data are represented as mean ± SD. *p < 0.05; n.s., not significant.

(B) Comparison of p53, αSMA, and fibronectin expression in mice tumors injected with ntsh-sEVs and shP53-sEVs according to IHC. The IHC score was analyzed based on the expression area and calculated using the IHC toolbox in the ImageJ software program. Data are represented as mean ± SD. *p < 0.05; n.s., not significant. Scale bar, 100 μm.

(C) Tumor weights obtained from mice inoculated with HT29-ntsh and -shP53 cells orthotopically. Data are represented as mean ± SD. n.s., not significant.

(D) Comparison of p53, αSMA, and fibronectin expression in the HT29-ntsh and HT29-shP53 groups based on an IHC assay. HPF, high-power field. The IHC score was analyzed based on the expression area and calculated using the IHC toolbox in the ImageJ software program. Data are represented as mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001. Scale bar, 100 μm.

(E) The populations of fibroblasts positive for the surface maker PDGFR-α as revealed by FACS flow cytometry. SSC, side scatter; FSC-A, forward scatter area.

(F) The quantitative real-time RT-PCR results for Trp53, FAP, IL1B, CXCL12, MMP2, and MMP9 in fibroblasts isolated from tumors using FACS. Data are represented as mean ± SD.

See also Figure S5.